. Eligibility criteria (continued)
Prohibited concomitant medications
 All central nervous system (CNS)-active therapies commonly used to treat fibromyalgia  Anorectics (eg, diethylpropion, sibutramine, phentermine, ephedrine, ma huang)  Antidepressants (eg, MAO-A or -B inhibitors, tricyclic or tetracyclic antidepressants, SSRIs, SNRIs, NRIs)  Antiepileptic agents (eg, phenytoin, topiramate, carbamazepine, levetiracetam, tiagabine, gabapentin, pregabalin)  Opiates and related analgesics (eg, oxycodone, codeine, tramadol, narcotic patches)  Dopamine agonists (eg, ropinirole, pramipexole)  Stimulants (eg, dextroamphetamine mixed salts, methylphenidate, dextroamphetamine, modafinil, ephedrine, ma huang, atomoxetine)  Muscle relaxants (eg, tizanidine, metaxalone, methocarbamol, carisoprodol)  Miscellaneous excluded medications (eg, buspirone, sodium oxybate)
Allowed concomitant medications
 5-hydroxytryptamine agonists (triptans) for migraines, with caution; Investigators were informed about serotonin syndrome or neuroleptic malignant syndrome-like reactions  Combination agents consisting of butalbital, aspirin/acetaminophen, and caffeine for headaches; required discontinuation of these medications for at least 1 week prior to study visits  Acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs  Sleep medications (eg, nonbenzodiazepine hypnotics per Investigator's judgment, antihistamines, chloral hydrate)  Epinephrine for severe allergic reaction; cautioned use of local anesthetics that contain epinephrine  Nasal decongestants containing pseudoephedrine or herbal supplements containing stimulants, with cautioned use after consultation with Investigator  Nonpharmacologic treatments (eg, physical therapy, acupuncture, chiropractic manipulation, massage therapy, cognitive behavioral therapy, psychological therapy, biofeedback) that were initiated >30 days prior to screening and continued without major change during the study DBP=diastolic blood pressure, n=number of patients meeting PCS criteria, N=number of patients with ≥1 postbaseline assessment, PCS=potentially clinically significant, SBP=systolic blood pressure. ALT (SGPT)=alanine aminotransferase (serum glutamic-pyruvic transaminase), AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); LLN=lower limit of normal range; n=number of patients meeting PCS criteria, N=number of patients with a non-PCS baseline and ≥1 post-baseline assessment, PCS=potentially clinically significant, ULN=upper limit of normal range. Figure shows all TEAEs that were reported in ≥2% of patients in the safety population.
